Processa Pharmaceuticals Inc (PCSA) concluded trading on Wednesday at a closing price of $0.26, with 9.21 million shares of worth about $2.39 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -80.32% during that period and on April 30, 2025 the price saw a gain of about 12.38%. Currently the company’s common shares owned by public are about 5.27M shares, out of which, 4.63M shares are available for trading.
Stock saw a price change of 7.78% in past 5 days and over the past one month there was a price change of -30.32%. Year-to-date (YTD), PCSA shares are showing a performance of -70.83% which decreased to -88.01% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.15 but also hit the highest price of $3.10 during that period. The average intraday trading volume for Processa Pharmaceuticals Inc shares is 2.10 million. The stock is currently trading 0.31% above its 20-day simple moving average (SMA20), while that difference is down -32.99% for SMA50 and it goes to -73.97% lower than SMA200.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) currently have 5.27M outstanding shares and institutions hold larger chunk of about 1.88% of that.
The stock has a current market capitalization of $1.36M and its 3Y-monthly beta is at 1.37. It has posted earnings per share of -$3.89 in the same period. It has Quick Ratio of 1.22 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PCSA, volatility over the week remained 14.16% while standing at 31.39% over the month.
Analysts are in expectations that Processa Pharmaceuticals Inc (PCSA) stock would likely to be making an EPS of -0.77 in the current quarter, while forecast for next quarter EPS is -0.65 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.77 which is -0.77 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -1.11 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 75.19% while it is estimated to increase by 10.42% in next year. EPS is likely to grow at an annualized rate of 42.65% for next 5-years, compared to annual growth of 22.65% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on April 25, 2024 offering a Buy rating for the stock and assigned a target price of $8 to it.
